Symbols

TLPH

Talphera·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TLPH

Talphera, Inc.

A specialty pharmaceutical company that develops therapies for acute post-operative pain and cancer breakthrough pain

Industry

Pharmaceutical

Established Date

07/13/2005

Listing Date

02/11/2011

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.talphera.com

Security Type

Common stock

Office address

1850 Gateway Drive, Suite 175, San Mateo, CA 94404

Business

Introduction

Talphera, Inc., was originally registered in Delaware as SuRX, Inc., on July 13, 2005. The company subsequently changed its name to AcelRx Pharmaceuticals, and the company changed its name from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc." on January 10, 2024. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for medical monitoring settings, with current R&D efforts focused on the regional anticoagulant Niyad for the dialysis circuit and the possible development of LTX-608 for other indications.

Company Financials

EPS

TLPH has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected -0.16, beating expectations. The chart below visualizes how TLPH has performed over recent quarters, highlighting trends in earnings surprises.